The appropriateness of curettage and electrodesiccation for the treatment of basal cell carcinomas

Clinical, Dermoscopic and Histopathological Features of Non-melanoma Skin Cancers in People With Skin of Colour: A Series of Five Cases

Non-melanoma skin cancers (NMSC) such as basal cell carcinoma (BCC) as well as squamous cell carcinoma (SCC) are the two most common skin malignancies globally. They are observed more frequently among Caucasians than Asians, and their incidence is inversely proportional to the pigmentation levels. Even though the occurrence of skin cancers in India is lower, the absolute quantity of cases may be considerable due to the vast population. Here, we report five cases of NMSC in people having skin of colour.

Cost analysis: Mohs micrographic surgery

BACKGROUND

With the continuing increase in the incidence of skin cancer, delivery of cost-efficient skin cancer treatment is a top priority.

OBJECTIVE

To compare costs associated with removal of skin cancers using Mohs micrographic surgery (MMS) with that using standard surgical excision (SSE) with frozen or permanent margin control in the office or an ambulatory surgery center (ASC).

METHODS AND MATERIALS

Costs for actual MMS and calculated costs for all SSE were recorded. The expense of treatment of incomplete excisions with subsequent reexcision and reconstruction and MMS on recurrent tumors were added to the final estimate.

RESULTS

Four hundred six tumors were included in the study. An average tumor was cleared in 1.6 stages. MMS was the least expensive surgical procedure evaluated, at $805 per tumor. SSE with permanent margins ($1,026) was more expensive than MMS but less expensive than SSE with frozen margins ($1,200) and ASC-SSE with frozen margins ($2,507). Adjusted for inflation, the cost of MMS, inclusive of initial examination, biopsy, and 5-year follow-up, in 2009 ($1,376) was lower than in 1998 ($1,635).

CONCLUSIONS

This study confirms MMS as the cornerstone of cost-effective treatment, regardless of place of service or type of margin control pathology.

Nonmelanoma skin cancer in India: current scenario

Incidence of skin cancers has been increasing since the last few decades worldwide. Nonmelanoma skin cancer (NMSC) is the commonest variety of cutaneous malignancy. Conventional wisdom has it that the incidence of all varieties of skin cancers is lower among Indians due to the protective effects of melanin. Though national surveys and cross-country data in India are unavailable, there are indirect indications from several smaller reports that NMSCs may be on the rise in India. Reports of quite a few atypical cases lead us to hypothesize that factors other than ultraviolet radiation may be important in the occurrences of these cancers, particularly in the skin types prevalent in India. The descriptive epidemiology and clinical characteristics of squamous and basal cell carcinoma in India, including their variants, are discussed here along with hypotheses on their etiopathogenesis. Novel management techniques currently available in India are also highlighted.

Treatment options for premalignant and malignant cutaneous tumors

Whenever possible, surgical excision of skin cancers should be the gold standard of treatment. There are many considerations when choosing one treatment modality over another. These include the lesion's location, the surgeon's experience and comfort level, the patient's health status and their potential compliance, access to available technology, and economic considerations for the patient and the provider. Regardless of the type of therapy, all forms of treatment share the following goals: complete disease cure, preservation of normal tissue, preservation of function, and optimal cosmesis.

Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation

BACKGROUND

The incidence of basal cell carcinoma (BCC) is increasing. Curettage and electrodesiccation (CE) are not recommended for BCC treatment at medium- and high-risk facial sites. Surgical excision has been proposed as the treatment of choice.

OBJECTIVE

We sought to evaluate the cumulative recurrence rate (RR) of primary BCC in facial areas of medium and high risk after CE.

METHODS

This nonrandomized, clinical trial enrolled 257 patients with primary BCC located in medium- and high-risk facial areas, and treated with 4 or 5 cycles of CE by a single operator from a section specializing in BCC CE in a tertiary teaching hospital in Oviedo, Spain. Exclusion criteria for study entry included: recurrent BCC, fibrosing BCC, ill-defined BCC, and BCC larger than 10 mm in diameter (high-risk facial sites) or larger than 15 mm in diameter (medium-risk sites); BCC smaller than 4 mm; and nonbiopsy-proven BCC. BCCs included in the study were from the nose, and paranasal and nasal-labial fold (n = 105); eyelids and canthi (n = 48); perioral areas (n = 12); ears (n = 11); forehead and temples (n = 48); periauricular areas (n = 14); and malar areas and cheeks (n = 19). The primary outcome was recurrence of carcinoma, which was clinically evaluated by at least two observers in consensus. Data were analyzed using both a life table method and Kaplan-Meier analysis. The statistical analysis included best- and worst-case scenarios (which means that all cases lost to follow-up were considered as recurrences).

RESULTS

The 5-year cumulative non-RR in the best-case scenario was 98.80% (SE 0.70, 95% confidence interval 97.40%-100%); thus, a 5-year cumulative RR of 1.20% was found after CE in our medium- and high-risk BCCs of the face (best case). The 5-year cumulative non-RR in the worst-case scenario was 79.40% (95% confidence interval 78.90%-79.90%); thus, a 5-year cumulative RR of 20.60%.

LIMITATIONS

Retrospective design with a relatively small number of patients lost to follow-up is a study limitation.

CONCLUSION

High 5-year cure rates can be obtained after CE of primary, nonfibrosing BCCs of medium- and high-risk areas of the face performed in a specialized section.

Topical and light-based treatments for basal cell carcinoma

Nonsurgical methods of treatment providing cure rates approaching those provided by surgery offer a significant advantage to patients with basal cell carcinoma (BCC) in certain anatomic locations. While intralesional interferon has been used to treat BCC with some success, the deliver method requires multiple visits to the doctor's office, which makes compliance a challenge for the patient. Initial success with light-based therapy of BCC over a decade ago has not evolved to the point where it is an effective, widely available treatment. The new class of immune response modifiers, represented by topical imiquimod cream, shows promise for providing topical treatment of early BCC. It is hoped that further developments of the class of drugs will produce an agent with fewer side effects and improved efficacy for nodular BCC.

Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodesiccation-curettage in a private dermatological practice

BACKGROUND

The incidence of nonmelanoma skin cancer, the most common form of cancer in the United States, continues to increase. It is important that physicians know what treatment modalities will be the most efficacious.

OBJECTIVE

The purpose of this study was to compare recurrence rates by treatment modality for primary basal and squamous cell carcinomas in a private dermatological practice.

METHODS

Between June 1993 and December 1994, 268 consecutive primary nonmelanomic tumors were treated by surgical excision or electrodesiccation and curettage in our practice. The charts of the 191 patients treated were retrospectively reviewed, and recurrence data were compared by treatment modality.

RESULTS

The recurrence rates between the two types of treatment were not found to be significantly different.

CONCLUSION

In contrast to other studies reported from academic centers in which surgical excision has been found to have lower recurrence rates than tumors treated with curettage and electrodesiccation, this study found recurrence rates for two treatments to be approximately the same.